Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 14
2021 11
2022 5
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
Liu J, Shen Y, Wen Z, Xu Q, Wu Z, Feng H, Li Z, Dong X, Huang S, Guo J, Zhang L, Chen Y, Li W, Zhu W, Du H, Liu Y, Wang T, Chen L, Teboul JL, Annane D, Chen D. Liu J, et al. Front Immunol. 2021 Aug 2;12:673693. doi: 10.3389/fimmu.2021.673693. eCollection 2021. Front Immunol. 2021. PMID: 34408744 Free PMC article.
BACKGROUND: Thymosin alpha 1 (Talpha1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear. This study aimed to explore the efficacy of Talpha1 as a COVID-19 therapy. METHODS: We performed …
BACKGROUND: Thymosin alpha 1 (Talpha1) is widely used to treat patients with COVID-19 in China; however, …
Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
Li X, Liu L, Yang Y, Yang X, Wang C, Li Y, Ge Y, Shi Y, Lv P, Zhou H, Luo P, Huang S. Li X, et al. Int Immunopharmacol. 2021 Jan;90:107022. doi: 10.1016/j.intimp.2020.107022. Epub 2020 Sep 18. Int Immunopharmacol. 2021. PMID: 33160854 Free PMC article.
Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection. Whether the immune response to Talpha1 treatment for SARS-CoV-2 differs between the sexes, …
Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVI …
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI. Soeroto AY, et al. Inflammopharmacology. 2023 Dec;31(6):3317-3325. doi: 10.1007/s10787-023-01354-2. Epub 2023 Oct 16. Inflammopharmacology. 2023. PMID: 37845598
This study's goal is to determine whether thymosin alpha-1 is effective in treating people with moderate-to-severe COVID-19. ...CONCLUSION: Our study suggests that treatment with thymosin alpha-1 may reduce mortality rate in …
This study's goal is to determine whether thymosin alpha-1 is effective in treating people with moderate-to-severe C …
Thymosin alpha 1: A comprehensive review of the literature.
Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, Thevuthasan S, Khan MA, Mathew A, Makkar SS, Zaidi M, Fahem MMM, Beas R, Castaneda V, Paul T, Halpern J, Baralt D. Dominari A, et al. World J Virol. 2020 Dec 15;9(5):67-78. doi: 10.5501/wjv.v9.i5.67. World J Virol. 2020. PMID: 33362999 Free PMC article. Review.
Studies have postulated that thymosin alpha 1 could help improve the outcome in severely ill corona virus disease 2019 patients by repairing damage caused by overactivation of lymphocytic immunity and how thymosin alpha 1 could prevent th …
Studies have postulated that thymosin alpha 1 could help improve the outcome in severely ill corona virus disease 2019 …
Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Wang Z, Chen J, Zhu C, Liu L, Qi T, Shen Y, Zhang Y, Xu L, Li T, Qian Z, Steinhart CR, Lu H. Wang Z, et al. Front Immunol. 2021 Jun 3;12:568789. doi: 10.3389/fimmu.2021.568789. eCollection 2021. Front Immunol. 2021. PMID: 34149679 Free PMC article.
Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Talpha1) is used in the management of COVID-19, because it is known to restore the homeostasis of the immune system during infections and cancers …
Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Talpha1) is used in …
Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.
Huang C, Fei L, Xu W, Li W, Xie X, Li Q, Chen L. Huang C, et al. Front Med (Lausanne). 2021 Apr 23;8:664776. doi: 10.3389/fmed.2021.664776. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33968969 Free PMC article.
Objective: Thymosin alpha 1 (Thymosin-alpha1) is a potential treatment for patients with COVID-19. ...Compared with the control group, the Thymosin-alpha1 group had significantly shorter SARS-CoV-2 RNA shedding duration (13 …
Objective: Thymosin alpha 1 (Thymosin-alpha1) is a potential treatment for patients with COVID-19. ...Com …
The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2.
Espinar-Buitrago MS, Tarancon-Diez L, Vazquez-Alejo E, Magro-Lopez E, Genebat M, Romero-Candau F, Leal M, Muñoz-Fernandez MA. Espinar-Buitrago MS, et al. Immun Ageing. 2023 Jul 5;20(1):32. doi: 10.1186/s12979-023-00351-x. Immun Ageing. 2023. PMID: 37408063 Free PMC article.
Our study aims to further in vitro effect of human Thymosin-alpha-1 (alpha1Thy) treatment on the immune system in population groups with different thymic function levels in the scenario of SARS-CoV2 infection. ...In addition, the effect on the T immune respon …
Our study aims to further in vitro effect of human Thymosin-alpha-1 (alpha1Thy) treatment on the immune system in popul …
COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections.
Bellet MM, Renga G, Pariano M, Stincardini C, D'Onofrio F, Goldstein AL, Garaci E, Romani L, Costantini C. Bellet MM, et al. Int Immunopharmacol. 2023 Apr;117:109949. doi: 10.1016/j.intimp.2023.109949. Epub 2023 Mar 2. Int Immunopharmacol. 2023. PMID: 36881979 Free PMC article. Review.
The recent COVID-19 pandemic has catalyzed the attention of the scientific community to the long-standing issue of lower respiratory tract infections. ...In this review, we will take advantage from the recent work on the COVID-19 pandemic to reassess t …
The recent COVID-19 pandemic has catalyzed the attention of the scientific community to the long-standing issue of lower respi …
Thymosin alpha1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.
Bai H, Liang L, Qi X, Xu Y, Liu Y, Ren D, Cai Z, Mao W, Wang X, Qin H, Hu F, Shi B. Bai H, et al. Int Immunopharmacol. 2023 Nov;124(Pt B):110983. doi: 10.1016/j.intimp.2023.110983. Epub 2023 Sep 26. Int Immunopharmacol. 2023. PMID: 37769533
BACKGROUND: The Coronavirus disease-19 (COVID-19) pandemic has posed a serious threat to global health. ...The differential expression analysis and functional enrichment analysis were performed to explore the mechanism of Talpha1 therapy. RESULTS: 33 symptoma …
BACKGROUND: The Coronavirus disease-19 (COVID-19) pandemic has posed a serious threat to global health. ...The differen …
Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.
Shang W, Zhang B, Ren Y, Wang W, Zhou D, Li Y. Shang W, et al. Int Immunopharmacol. 2023 Jan;114:109584. doi: 10.1016/j.intimp.2022.109584. Epub 2022 Dec 13. Int Immunopharmacol. 2023. PMID: 36527881 Free PMC article. Review.
OBJECTIVE: Thymosin alpha1 (Ta1) is widely used to treat patients with coronavirus disease 2019 (COVID-19), however, its effect remains unclear. ...CONCLUSIONS: The results of this meta-analysis do not support the use of Ta1 in hospitalized adult COVID …
OBJECTIVE: Thymosin alpha1 (Ta1) is widely used to treat patients with coronavirus disease 2019 (COVID-19), however, it …
40 results